NeurAxis, Inc. (NRXS)
| Market Cap | 75.85M +211.5% |
| Revenue (ttm) | 5.32M +65.2% |
| Net Income | -8.45M |
| EPS | -0.78 |
| Shares Out | 12.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 73,899 |
| Open | 6.10 |
| Previous Close | 6.07 |
| Day's Range | 6.00 - 6.23 |
| 52-Week Range | 2.21 - 9.33 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+82.12%) |
| Earnings Date | Aug 11, 2026 |
About NRXS
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation di... [Read more]
Financial Performance
In 2025, NeurAxis's revenue was $3.57 million, an increase of 32.89% compared to the previous year's $2.69 million. Losses were -$8.62 million, 1.92% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NRXS stock is "Strong Buy." The 12-month stock price target is $11.0, which is an increase of 82.12% from the latest price.
News
NeurAxis Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 116% YoY to $1.93M, with gross margin expanding to 85.9% and strong progress in insurance coverage and VA channel expansion. Cash burn improved, but future profitability depends on securing additional payer coverage and continued commercial execution.
NeurAxis Quarterly report: Q2 2026
NeurAxis has published its Q2 2026 quarterly earnings report on August 11, 2026.
NeurAxis Earnings release: Q2 2026
NeurAxis released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
NeurAxis Expands Payer Coverage with New Policies
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic a...
NeurAxis Registration statement: Registration filing
NeurAxis filed a registration statement on July 30, 2026, providing details about a securities offering with the SEC.
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
Neuraxis files to sell 1.92M shares of common stock for holders
16:44 EDT Neuraxis (NRXS) files to sell 1.92M shares of common stock for holders
NeurAxis Registration statement: Registration filing
NeurAxis filed a registration statement on July 23, 2026, providing details about a securities offering with the SEC.
NeurAxis Transcript: Lytham Partners Spring 2026 Investor Conference
The company reported record Q1 revenue and strong gross margins, driven by expanded insurance coverage and a new Category 1 CPT code. Commercial efforts are focused on pediatric and VA markets, with new hires and resumed commercialization of the RED device supporting growth.
NeurAxis Slides: Investor presentation
NeurAxis has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
NeurAxis Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 80% year-over-year to $1.6 million, with gross margin expanding to 86.4% and cash burn declining. Commercial focus is on deepening adoption in covered pediatric markets and expanding VA presence, while payer coverage and execution remain key growth drivers.
NeurAxis Quarterly report: Q1 2026
NeurAxis has published its Q1 2026 quarterly earnings report on May 12, 2026.
NeurAxis Earnings release: Q1 2026
NeurAxis released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic a...
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ch...
NeurAxis Proxy statement: Proxy filing
NeurAxis filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
NeurAxis Proxy statement: Proxy filing
NeurAxis filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
NeurAxis Expands Payer Coverage with Four New Medical Policies
CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
NeurAxis, Inc. Announces Preferred Stock Dividend
CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
Neuraxis price target raised to $13 from $8 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Neuraxis (NRXS) to $13 from $8 and keeps a Buy rating on the shares after Q1 results, which exceeded expectations…
NeurAxis Earnings Call Transcript: Q4 2025
Q4 and FY 2025 saw double-digit revenue growth, major payer wins, and expanded reimbursement access, with strong operational execution and a robust commercial strategy for 2026. Gross margins remained high despite product mix shifts, and liquidity is sufficient for growth plans.
NeurAxis Earnings release: Q4 2025
NeurAxis released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
NeurAxis Annual report: Q4 2025
NeurAxis has published its Q4 2025 annual report on March 19, 2026.
Neuraxis reports Q4 revenue $968K vs. $761K last year
Reports Q4 net loss ($1.7M), up 18% vs. ($1.4M) in 4Q24. CEO Brian Carrico commented: “We believe NeurAxis (NRXS) has entered a new phase of its growth trajectory. With the…
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...